Gibson Oncology's LMP744 Advances to Phase II: First Patient Completes Initial Treatment Cycle in Recurrent Glioblastoma Trial
核心洞察
The first patient in the Phase II trial of LMP744 for recurrent glioblastoma (搜索) has completed the initial treatment cycle without complication, marking an important early milestone.
LMP744 is a novel dual-acting agent that reduces cMyc (搜索) oncogene overexpression and inhibits topoisomerase 1 (搜索), with demonstrated blood-brain-barrier penetration in preclinical studies.
The NINDS-conducted trial will enroll 40 first-time recurrent GBM patients, with progression-free survival as the primary endpoint and overall survival as the secondary endpoint.
The first patient enrolled in the Phase II clinical trial of LMP744 has completed the initial treatment cycle without complication, Gibson Oncology (搜索) announced on August 11, 2026. The trial, conducted by investigators at the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, is evaluating LMP744 as a single agent in patients with recurrent glioblastoma (搜索) (GBM). Gibson Oncology is providing partial funding and the investigational agent under a Clinical Cooperative Research and Development Agreement (CRADA) with NINDS.
"Completing the first treatment cycle in this trial is an important early milestone for LMP744 and, most of all, for the patients who face recurrent glioblastoma (搜索) with limited therapeutic options, and one of the most difficult cancers in medicine," said Randall Riggs, President and Chief Executive Officer of Gibson Oncology (搜索).
Dual Mechanism Targets Unmet Need in Brain Tumors
LMP744 is a novel, dual-acting indenoisoquinoline that works by reducing overexpression of the cMyc (搜索) oncogene and by inhibiting topoisomerase 1 (搜索) (TOPO1), two validated targets across a range of solid and hematological cancers. The agent has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for all gliomas, including DIPG.
Glioblastoma remains the most common and aggressive primary brain tumor in adults, with approximately 13,000 new cases diagnosed in the United States each year. Median survival is generally 15 to 18 months, and the five-year survival rate falls below 10 percent. For patients with recurrent glioblastoma (搜索), the prognosis is especially poor, as there is no established standard of care.
Blood-Brain Barrier Penetration: A Critical Differentiator
Blood-brain-barrier penetration has long been one of the central obstacles in the treatment of brain tumors. In preclinical studies, LMP744 crossed the blood-brain barrier and achieved brain concentrations approximately 10 times the level needed to kill cancer cells, with a half-life in the brain exceeding 24 hours for each dose.
"The renewed excitement about LMP744 is two-fold," Riggs explained. "First, LMP744 was found to migrate rapidly into the brain at high concentrations, well beyond the levels needed to kill cancer, with each dose having a half-life of over 24 hours. Second, in PDX animal models implanted with patient-derived recurrent gliomas, just five doses of LMP744 produced tumor eradication. Together, these findings made a compelling case for initiating this Phase II study at the NINDS."
Phase II Trial Design and Prior Clinical Experience
The Phase II trial is designed to enroll a total of 40 first-time recurrent GBM patients with a Karnofsky Performance Status (KPS) of 60 or better. The primary endpoint is progression-free survival, with overall survival as a secondary endpoint. LMP744 is being studied as a single therapeutic agent based on the strong anticancer effects observed in GBM patient-derived xenograft (PDX) animal models.
LMP744 previously completed a Phase I clinical trial involving 36 heavily pretreated cancer patients, many of whom had failed as many as eight prior individual or combination treatments. In that study, over 30% of patients on single-agent treatment with LMP744 experienced stable disease for up to 30 months, and two patients were partial responders. These results were achieved even though many patients were sub-optimally dosed to establish the drug's safety and tolerability before reaching the therapeutic dose level of 190 mg/m².
Gibson Oncology (搜索) is also developing LMP400, a second blood-brain-barrier-penetrant candidate targeting Grade 3 and Grade 4 astrocytomas resistant to standard of care, along with a next-generation series of Aza compounds. The company holds Rare Pediatric Disease Designation for Ewing sarcoma in addition to its Orphan Drug Designation for all gliomas.